Edgen Stock·Sep 19 2025, 01:13戻る
戻る
Pfizer's KAT6 Inhibitor PF-07248144 Advances to Phase 3 for HR+ HER2- Breast Cancer
Edgen Stock·Sep 19 2025, 01:13
[1] Jointly discovered KAT6i molecule originating from Australian research has initiated Phase 3 in HR+ HER2- Breast Cancer with Pfizer Inc[2] KAT6 marks another phase 1-to-3 push from Pfizer | ApexOnco - Oncology Pipeline[3] Telomir Pharmaceuticals: Pioneering Epigenetic Therapies with a First-Mover Edge in Multi-Target Histone Demethylase Inhibition - AInvest